Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Thomas M Shiovitz MD Inc

Neither a doctor nor a teaching hospital

Research payments

$3,827,932

58 payments

Through program year 2025, Thomas M Shiovitz MD Inc is reported as receiving $3,827,932 in research payments, across 58 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $506,535 7
2024 Research $841,164 8
2023 Research $1,448,804 10
2022 Research $492,234 7
2021 Research $446,109 14
2020 Research $74,353 9
2019 Research $18,733 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $3,684,253 31 payments
  2. Sage Therapeutics, Inc. $71,684 8 payments
  3. Biohaven Pharmaceuticals, Inc. $34,469 10 payments
  4. Pfizer Inc. $14,193 3 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $10,594 1 payment
  6. Biohaven Pharmaceutical Holding Company Ltd. $9,147 4 payments
  7. Janssen Research & Development, LLC $3,592 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $937,131 2 payments
  2. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $830,256 7 payments
  3. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $727,277 4 payments
  4. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $433,285 2 payments
  5. A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $282,652 4 payments
  6. A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $227,130 4 payments
  7. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $139,968 3 payments
  8. A Phase 3 Open-Label Parallel-Group 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $62,496 2 payments
  9. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $33,893 5 payments
  10. A Study of Donanemab (Ly3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (Trailblazer-Alz 4) $28,917 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record